“…This form of injury and its associated behavioral deficits can be recapitulated in rodent models, which may therefore be useful for discovery and validation of new therapeutic approaches (Goldstein et al, 2012; Mohan et al, 2013; Yin et al, 2014). Pharmcologic agents shown to enhance flux of the nicotinamide adenine dinucleotide (NAD) salvage pathway in normal mammalian cells and facilitate NAD rebound following doxorubicin exposure (Pieper et al, 2010, 2014; MacMillan et al, 2011; Wang et al, 2014) confer protective efficacy on pathology and behavior in a rodent model of blast-mediated TBI (Yin et al, 2014), as well as other models of neurodegeneration in the central and peripheral nervous systems (De Jesús-Cortés et al, 2012, 2015,2016; Tesla et al, 2012; Blaya et al, 2014; Dutca et al, 2014; Naidoo et al, 2014; Kemp et al, 2015; Walker et al, 2015; Lee et al, 2016). In addition, treatment with NAD and NAD precursors, including nicotinamide, nicotonic acid mononucleotide, and nicotinamide mononucleotide (NMN), or overexpression of nicotinamide phosphoribosyltransferase protect axons in vitro (Araki et al, 2004; Wang et al, 2005; Sasaki et al, 2006).…”